

Performance & Organization of most successful mid pharma companies

— Short version —

"New business strategies consist in doing different things while new business models consist in doing things differently"

Confidential

January 2015



1, rue Houdart de Lamotte – 75015 Paris – France Tel.: +33 6 11 96 33 78 – Fax: +33 1 45 57 46 59 E-mail: jmpeny@smart-pharma.com Website: www.smart-pharma.com

Table of Contents

- 1. Introduction
- 2. Screening of companies
- 3. Key success factors of high performers
 - Gilead
 - Biogen Idec
 - Celgene
- 4. How to move from a pharma to a biopharma company **BMS**
- 5. A company in the company Sanofi Diabetes
- 6. Key learnings
- 7. Appendices



1. Introduction

Smart Pharma has studied the three most profitable mid-pharma companies and two Big-pharma having implemented specific strategic and organizational changes

Key points of the presentation -

- The **performances** of pharma companies may **vary significantly** from one to another
- Their performances are not only driven by strategic decisions...
- ... but also by organizational models
- Thus, Smart Pharma Consulting has selected and analyzed the key strategic and organizational drivers which support the three mid-size best performing companies amongst the Top 50 ones, in 2013:
 - Biogen Idec
 - Celgene
 - Gilead
- Smart Pharma Consulting has also tried to understand why and how:
 - **BMS** moved from a primary care to a secondary care focus business model?
 - **Sanofi** has decided to create a fully-integrated structure encompassing its diabetes business


Sources: Smart Pharma Consulting analyses



2. Screening of companies

Smart Pharma Consulting proposes a methodology to identify pharma companies having shown the best economic performance in the world over the 2011-2013 period

- Methodology to identify high performing mid-pharma companies -



4

Sources: ¹ Pharma 50 ranking as published by Pharmaceutical Executive in June 2014, Smart Pharma Consulting analyses

Performance & Organization of most successful mid pharma companies



2. Screening of companies

Gilead, Biogen Idec and Celgene are the most profitable mid-pharma companies among mid-pharma over the 2011-2013 period

	Operating Income (USD million*)									
Company Name	2013	% of revenues	2012	% of revenues	2011	% of revenues	2011-2013	% of revenues	2011-2013	
Gilead	4,524	40.4%	4,010	41.3%	3,790	45.2%	12,324	42.1%	9.3%	
Biogen Idec	2,516	36.3%	1,856	33.6%	1,725	34.2%	6,097	34.8%	20.8%	
Celgene	1,809	27.9%	1,746	31.7%	1,443	29.8%	4,998	29.7%	12.0%	
Allergan	1,809	28.7%	1,611	28.5%	1,375	26.4%	4,795	27.9%	14.7%	
Shire	1,733	35.1%	1,045	23.1%	1,136	27.3%	3,914	28.7%	23.5%	
CSL ¹	1,658	30.0%	1,509	29.4%	1,255	27.1%	4,422	28.9%	14.9%	
Sun Pharma ²	1,184	43.0%	820	42.3%	561	39.9%	2,565	42.0%	45.3%	
Grifols	978	26.8%	877	25.2%	371	15.5%	2,226	23.4%	62.4%	
Chugai	807	18.6%	765	19.3%	640	16.7%	2,212	18.2%	12.3%	
Aspen ¹	715	25.2%	486	26.1%	380	25.8%	1,581	25.6%	37.3%	

Selected high performing mid-pharma companies – Top 3

* Restated at constant rates currency using the 2013 Federal Reserve average exchange rates

Sources: Annual reports - Smart Pharma Consulting analyses


 1 Revenues as at 30 June 2014, 30 June 2013 and 30 June 2012 – 2 Revenues as at 31 March 2014, 31 March 2013 and 31 March 2012

Performance & Organization of most successful mid pharma companies



3. Key success factors of high performers

Gilead, Biogen and Celgene are innovative companies with R&D rates higher than the average that have successfully optimized their cost structure through partnerships



6

Gilead, Biogen Idec and Celgene KPIs -

Performance & Organization of most successful mid pharma companies



Gilead's deliberate limited sales forces and outsourced distribution activities can explain the relative low marketing and administrative costs

Gilead's high performance drivers (1/2) -

	In 2013, R&D expenses represented 19% of total revenues	Оре	erating m	hargin = 40	%
	7 R&D centers worldwide (6 in the US and 1 in Canada)	2013 revenues = \$ 1			В
R&D strategy	 Research programs are focused on 5 domains: infectiology, oncology, respiratory (pulmonary fibrosis and respiratory syncytial virus) and cardiovascular 	R&D expenses ¹			
Manufacturing processes		15%:	19% 26%		
		Market	ing and		
	 In 2013, marketing and administrative costs represented only 15% of total revenues 	admini	strative Manufactur sts ³ cost ²		
Commercialization and distribution	 Considering the added-value of its medicines, Gilead does not want to oversold its products and deliberately limits its sales forces 	Ke	y produc	cts analysi	s
	 In 2013, the 3 main wholesalers accounted for ~50% of the worldwide product sales 	Name	Share of 2013 revenues	Indication	Annual price / patient ⁴ (USD)
		Atripla	33%	VIH	10,548
Koyloorninge	Sales forces are deliberately limited and distribution activities are	Truvada	28%	VIH	7,177
Key learnings	extensively outsourced	Viread	9%	VIH and Hepatitis B	5,004

Note: See appendices for more details

Sources: External interviews – Smart Pharma Consulting analyses

¹ R&D expenses as a % of 2013 revenues – ² COGS as a % of 2013 revenues – ³ Marketing and administrative costs as a % of 2013 revenues – ⁴ Theoretical annual price for a French patient estimated on the basis of GERS extractions with an assumption of a 100% observance rate





The corner stone of Gilead's strategy seems to be the focus on life-threatening pathologies with unmet medical needs

Gilead's high performance drivers (2/2)



Sources: External interviews – Smart Pharma Consulting analyses



Biogen Idec's high profitability is notably driven by key partnerships that enable to optimize the manufacturing and distribution processes

Biogen Idec's high performance drivers (1/2) -

	In 2013, R&D expenses represented 21% of total revenues	Ор	erating m	argin = 40	%	
R&D strategy	2013 revenues = \$ 6.9 B R&D 21% expenses ¹					
Manufacturing processes	 In 2013, COGS represented 12% of total revenues There are 3 manufacturing facilities: 2 in the US and 1 in Denmark Manufacturing agreements with Roche Group for Rituxan and Gazyva Manufacturing agreement with Alkermes for Fampyra which is licensed from Acorda Therapeutics 	31% Marke admin c	12% Manufa co	ncturing st ²		
Commercialization	In most countries, marketing efforts are realized through own sales forces	Key products analysis				
and distribution	 Distribution activities are largely performed by wholesale distributors or by strategic partners (e.g. Roche Group for Gazyva) 	Name	Share of 2013 revenues	Indication	Annual price / patient ⁴ (USD)	
Koyloomingo	Key agreements signed with strategic partners (Elan, Roche	Avonex	43%	Multiple sclerosis	13,212	
Key learnings	Group, Alkermes)	Tysabri	22%	Multiple sclerosis	27,492	

9

Note: See appendices for more details

Sources: External interviews – Smart Pharma Consulting analyses

¹ R&D expenses as a % of 2013 revenues – ² COGS as a % of 2013 revenues – ³ Marketing and administrative costs as a % of 2013 revenues –⁴ Theoretical annual price for a French patient estimated on the basis of GERS extractions with an assumption of a 100% observance rate



Biogen Idec's motto seems to be linked with innovation on added-value treatments in secondary care diseases

Biogen Idec's high performance drivers (2/2) -

Strategic drivers	Organizational drivers
 Concentration on serious diseases with important unmet medical needs "We are already in 3 therapeutic areas: multiple sclerosis, hemophilia and cancer but we are also involved in the R&D in amyotrophic lateral sclerosis and other orphan diseases" 	 Research projects are mainly carried out internally Customer-centric enterprise: one of the pioneer of CRM in
Expertise in the selected pathologies, especially multiple sclerosis	biopharmaceutical companies
Innovative research: "Our goal is always to develop added-value for patients, either in terms of therapies or at least for their comfort" "We look for innovation in the pathologies we cover"	 Reps with high scientific background (Area business managers)
 Iinked with financing capacities: "As other biopharma companies, Biogen Idec has financing capacities allowing to invest in innovative R&D projects" 	 Limited human resources: 6,850 employees
 Customer-centricity approach: "We try to always have an innovative approach for patients" 	 Limited sales forces in comparison
 Willingness to develop partnerships to improve R&D: "I am convinced that partnerships can permit to find innovative molecules" 	with big-pharma companies



Sources: External interviews with 2 Biogen Idec collaborators – Bibliographic review – Smart Pharma Consulting analyses

Celgene's selling prices are much higher than the average of the industry, which allows the group to have a high profitability and to invest in many R&D programs

Celgene's high performance drivers (1/2) -

	5 R&D centers: 4 in the US and 1 in Spain	Ор	erating m	nargin = 40	%		
R&D strategy	 In 2013, R&D expenses were up to 34% of total revenues and research scientists represented ~40% of total headcount 	2013 revenues = \$ 6.5 B R&D					
	 R&D portfolio is focused on: hematology, oncology, inflammation, anemia and cellular therapies 						
Manufacturing processes	 3 manufacturing facilities: 1 in the US and 2 in Switzerland In 2013, COGS represented only 5% of total revenues, notably due to the selling prices of Celgene's key products, which is much higher than the average of the industry (including Gilead and Biogen Idec) 	Mark admi	33% Marketing and administrative costs ³				
Commercialization	 Brands are promoted globally through Celgene's commercial organization 	Key products analysis					
and distribution	 Distribution is generally handled by commonly used channels in local markets 	Name	Share of 2013 revenues	Indication	Annual price / patient ⁴ (USD)		
Kowloorpinge	R&D efforts are particularly high compared with the average of the industry	Revlimid	66%	Multiple myeloma	119,422		
Key learnings	 Profitability is driven by high sales prices 	Vidaza	12%	Multiple myeloma & leukaemia	138,903		

11

Note: See appendices for more details

Sources: External interviews – Smart Pharma Consulting analyses

¹ R&D expenses as a % of 2013 revenues – ² COGS as a % of 2013 revenues – ³ Marketing and administrative costs as a % of 2013 revenues –⁴ Theoretical annual price for a French patient estimated on the basis of GERS extractions with an assumption of a 100% observance rate

Performance & Organization of most successful mid pharma companies



3. Key success factors of high performers

R&D appears to be the pillar of the Celgene's strategy: it makes it possible to develop innovative medicines for particularly serious diseases

Celgene's high performance drivers (2/2)

Strategic drivers

- Intense research activity:
 - During the past 5 years, the company invested over 40% of its revenues in R&D. This figure is more than twice as much as the average in the pharma sector
 - With \$ 6.9 B in cash and marketable securities as of 30 September 2014, the company has the ability to continue to invest
- Thanks to its efficacy for treating multiple myeloma, Revlimid (Celgene's main key product) sees a growth in sales volume, not price dependent (despite the high price of the treatment)

Organizational drivers


- High level of entrepreneurial spirit:
 - "Celgene's employees are passionate about what they do"
 - People are encouraged to take responsibility for their personal development
- Learning and development culture
- Team spirit...
-strong agility
- Focus on science and R&D

Sources: Eternal interviews – «3 secrets to Celgene's future success from Q3 results », Keith Speights, October 24, 2013 – "5 things Celgene Corporation's Management wants you to know", Sean Williams, August 11, 2014 – Insights Discovery program presentation – Smart Pharma Consulting analyses

Performance & Organization of most successful mid pharma companies



BMS's profitability decline in 2012 was mainly due to the loss of exclusivity of Plavix, its main contributing brand



13

Sources: Annual reports - Smart Pharma Consulting analyses

¹ Mature products and all other revenues, that represent \$ 2,765 M in 2013, \$ 2,757 M in 2012, \$ 2,950 M in 2011, \$ 3,053 M in 2010, \$ 3,536 in 2009 and \$ 3,498 M in 2008, have been equally allocated between "primary care "and 'secondary care" categories



BMS became a biopharma company through acquisitions and partnerships, by divesting some TAs, some regions and by introducing innovative processes

How did BMS move to a biopharma company?

Acquisitions & partnerships ¹	Divestments	Productivity transformation	Innovative processes
 2008: Exclusive alliance with KAI Pharmaceuticals Inc to develop and commercialize KAI-9803 for cardiovascular disease 2008: Global collaboration with the biotech Exelixis for new diabetes and anti-inflammatory therapies 2009: Acquisition of Medarex, for \$ 2.4 B (ipilimumab rights, human antibody development system platform) 2010: Licensing agreement with Oncolys bioPharma for Investigational HIV 2012: Acquisition of Inhibitex for \$2.5 B, to compete in HCV 2013: Partnership with Simcere for Orencia in China 2014: acquisition of iPierian for its anti-Tau programme for rare brain disorders 	 2008: sale of BMS Medical Imaging for \$ 525 M 2008: Sales of BMS portfolio and plant in Egypt to GSK 2009: BMS generics products in Lebanon, Jordan, Syria, Libya and Yemen sold to GSK 2011: BMS sell products' rights in Sri Lanka to GSK 2014: divestment of diabetes business to Astra Zeneca 	 2008: Productivity transformation Initiative, expected to result on \$ 2.5 B in annual productivity savings "An important productivity transformation initiative has been expanded and led to reset the cost base while fundamentally changing the way work is done to be quicker, more agile and more profitable. This strategy has been accompanied with organizational and cultural changes. The number of employees decreased from 55,000 to 22,000 worldwide and employees have been given more and more responsibilities" 	 Entrepreneurship approach "Our philosophy is to give responsibilities to collaborators in order to increase entrepreneurship and corporate agility. This supposes to develop the right to make mistakes. This kind of process takes time to implement" Customer centricity approach "We always try to think there is a patient behind our products" Trigger-marketing approach

14

Sources: Annual reports - External interviews - Smart Pharma Consulting analyses


¹ See appendices for more details



5. A company in the company – Sanofi Diabetes

Sanofi created a fully-integrated diabetes franchise to be more responsive and to become more competitive in a strategic therapeutic area dominated by Novo Nordisk

Why did Sanofi create a fully-integrated diabetes franchise?



Sources: External interviews – Pharma Consulting analysis



5. A company in the company – Sanofi Diabetes

The creation of a fully-integrated diabetes franchise seems to have improve Sanofi agility and competitiveness vs. smaller competitors such as Novo Nordisk

Pros & Cons of a fully-integrated diabetes franchise -

Cons
teractions with colleagues of to have more interactions with people working in puntries than with the ones that work in the same but in an other unit" e dependence to the corporate strategy
ve to share the corporate culture and many ses like the IT platform"
k independent but we are much less than Genzyme Pasteur or "the dengue company" that Sanofi ‹ created"
e dependence to the corporate funding
_


16

Sources: External interviews – Smart Pharma Consulting analyses

.



To keep their momentum, fast growing companies which operate in markets where changes become faster and more complex, need to be strategically agile




17

Sources: Adapted from Y. Doz & M. Kosonen, Smart Pharma Consulting analyses



To be effective and efficient, customer-centric strategies should be supported by an appropriate thinking process, including customer insights and adequate monitoring

Integrated customer-centricity strategy in the pharma sector




Performance & Organization of most successful mid pharma companies



High market sensitivity, simple and short processes, cross-departments coordination and cooperation to better serve customers will contribute to sustain strategic agility

Customer-centricity organization: The 4 Cs




19

Sources: Adapted from R. Gulati (HBR 2007), Smart Pharma Consulting analyses

Jan



The most profitable pharma companies have in common to be focused on innovative specialty treatments, to be customer-oriented and to benefit from with strong values



20

Sources: External interviews – Smart Pharma Consulting analyses



Fast growing companies, better than competition, offer their customers unique experiences with their products and services which induce lasting preference

Takeaways

- To increase their profitability, pharma companies should:
 - Rely on the leadership of a management team with solid credibility and strong communication skills that can embody positive and noble values
 - Define a strategic organization ensuring agility and customer-centricity
 - Set ambitious objectives, such as becoming the expert of a pathology
 - Design an organization to implement effectively and efficiently such a fast growing strategy:
 - Put the collaborators (internal customers) at the center of the system
 - · Institute a sense of urgency, especially vis-à-vis customers
 - Build a network of market sensors to maintain a competitive edge
 - Shorten and simplify business-driven processes
 - Automate, outsource or even have the "courage" to suppress control-driven processes when they do not create significant value
 - Focus on innovative secondary care treatments, with unmet medical needs

"Every decision – either strategic or organizational – should contribute to create customer preference"

Sources: Smart Pharma Consulting analyses

Performance & Organization of most successful mid pharma companies



Among the top 50 pharma companies, Smart Pharma Consulting has identified 11 companies exhibiting a double-digit annual growth rate over the 2011-2013 period

	Reve	enues (USD mi	llion*)	CAGR		Reve	enues (USD mi	illion*)	CAGR
Company Name	2013	2012	2011	2011-2013	Company Name	2013	2012	2011	2011-2013
Novartis	58,831	57,561	59,375	-0.5%	Actavis	8,678	5,915	4,584	37.6%
Johnson & Johnson ¹	56,615	52,777	50,147	6.3%	Biogen Idec	6,932	5,516	5,049	17.2%
Pfizer	51,584	54,657	61,035	-8.1%	Mylan	6,910	6,796	6,130	6.2%
Roche	45,058	43,975	40,888	5.0%	Celgene	6,494	5,507	4,843	15.8%
Sanofi	44,235	47,756	46,562	-2.5%	Allergan	6,301	5,646	5,216	9.9%
Merck & Co	44,033	47,267	48,047	-4.3%	Eisai ³	6,026	5,730	6,470	-3.5%
GlaxoSmithKline	43,822	43,786	43,756	0.1%	Valeant	5,769	3,481	2,427	54.2%
Fresenius	27,002	25,620	21,730	11.5%	Servier ³	~5,600			
AstraZeneca	25,711	27,973	33,591	-12.5%	CSL ⁴	5,525	5,129	4,624	9.3%
Bayer ²	25,134	24,709	22,803	5.0%	Shire	4,933	4,528	4,158	8.9%
Eli Lilly	23,672	23,391	24,286	-1.3%	UCB	4,540	4,598	4,311	2.6%
Abbott Laboratories	21,848	21,494	21,407	1.0%	Menarini	~4,400			
Teva	20,314	20,317	18,312	5.3%	Chugai	4,341	3,961	3,827	6.5%
Boehringer Ingelheim	20,225	21,542	19,295	2.4%	Mitsubishi Tanabe ³	4,121	4,185	4,089	0.4%
AbbVie	18,790	18,380	17,444	3.8%	Hospira	4,003	4,092	4,057	-0.7%
Amgen	18,676	17,265	15,582	9.5%	Dainippon Sumitomo ³	3,871	3,472	3,499	5.2%
Takeda ³	16,891	15,547	15,067	5.9%	Forest Laboratories ³	3,647	3,094	4,548	-10.5%
BMS	16,385	17,621	21,244	-12.2%	Grifols	3,642	3,481	2,384	23.6%
Baxter International	15,268	14,345	13,893	4.8%	Kyowa Hakko Kirin	3,490	3,414	3,522	-0.5%
Novo Nordisk	15,000	14,010	11,900	12.3%	Aspen Pharmacare ⁴	2,844	1,860	1,470	39.1%
Merck KGaA	14,736	14,839	13,649	3.9%	Sun Pharma ³	2,756	1,937	1,407	40.0%
Otsuka Holdings ³	14,506	12,162	11,528	12.2%	Lundbeck	2,716	2,635	2,850	-2.4%
Astellas Pharma ³	11,382	9,804	9,679	8.4%	STADA Arzneimittel	2,675	2,440	2,278	8.4%
Gilead Sciences	11,202	9,703	8,384	15.6%	Purdue Pharma	~2,200			
Daiichi Sankyo ³	11,166	9,932	9,373	9.1%	Ranbaxy Laboratories ⁵	1,820	2,156	1,792	0.8%

Top 50 pharma companies worldwide - Revenues

Big Pharma companies

Mid Pharma companies

Companies for which overall financial statements are not available

* Restated at constant rates currency using the 2013 Federal Reserve average exchange rates

Sources: Annual reports except for Servier, Menarini and Purdue Pharma for which information comes from their Web sites, Smart Pharma Consulting analyses

¹ Excluding the consumer segment -² Excluding crop science and material science segments - ³ Revenues as at 31 March 2014, 31 March 2013 and 31 March 2012 - ⁴ Revenues as at 30 June 2014, 30 June 2013 and 30 June 2012 - ⁵ Revenues as at 31 March 2014 (pro-rated on a 12 months basis) and as at 31 December 2012 and 31 December 2011

Performance & Organization of most successful mid pharma companies

22



Among the Mid Pharma companies, with a double-digit annual growth rate, Gilead, Biogen and Celgene are the most profitable

- Top 50 pharma companies worldwide - Operating income

		Operatir	ng Incom	ne (USD i	nillion <u>*)</u>		CAGR			Operatir	ng Inc <u>or</u>	ne (USD i	million*))	CAGR
Company Name	2013	% of revenues	2012	% of revenues	2011	% of revenues	2011- 2013	Company Name	2013	% of revenues	2012	% of revenues	2011	% of revenues	2011-2013
Pfizer	15,716	30.5%	11,242	20.6%	11,481	18.8%	17.0%	Allergan	1,809	28.7%	1,611	28.5%	1,375	26.4%	14.7%
Roche	15,179	33.7%	13,092	29.8%	12,470	30.5%	10.3%	Shire	1,733	35.1%	1,045	23.1%	1,136	27.3%	23.5%
GSK	10,993	25.1%	11,418	26.1%	12,097	27.6%	(4.7)%	CSL ⁴	1,658	30.0%	1,509	29.4%	1,255	27.1%	14.9%
Novartis	10,910	18.5%	11,511	20.0%	10,998	18.5%	(0.4)%	Sun Pharma ³	1,184	43.0%	820	42.3%	561	39.9%	45.3%
Sanofi	6,781	15.3%	8,416	17.6%	7,612	16.3%	(5.6)%	Astellas ³	1,152	10.1%	1,203	12.3%	1,313	13.6%	(6.3)%
Merck & Co	5,956	13.5%	9,213	19.5%	7,670	16.0%	(11.9)%	Mylan	1,136	16.4%	1,109	16.3%	1,005	16.4%	6.3%
Eli Lilly	5,929	25.0%	5,482	23.4%	5,456	22.5%	4.2%	Daiichi Sankyo ³	1,114	10.0%	986	9.9%	981	10.5%	6.6%
Amgen	5,867	31.4%	5,577	32.3%	4,312	27.7%	16.6%	Grifols	978	26.8%	877	25.2%	371	15.5%	62.4%
AbbVie	5,664	30.1%	5,817	31.6%	3,620	20.8%	25.1%	Chugai	807	18.6%	765	19.3%	640	16.7%	12.3%
Novo Nordisk	5,607	37.4%	5,247	37.5%	3,983	33.5%	18.6%	Aspen ⁴	715	25.2%	486	26.1%	380	25.8%	37.3%
Bayer ²	4,330	17.2%	2,929	11.9%	4,238	18.6%	1.1%	Eisai ³	663	11.0%	802	14.0%	956	14.8%	(16.7)%
Fresenius	3,972	14.7%	3,962	15.5%	3,404	15.7%	8.0%	Mitsubishi Tanabe ³	590	14.3%	689	16.5%	765	18.7%	(12.1)%
AstraZeneca	3,712	14.4%	8,148	29.1%	12,795	38.1%	(46.1)%	UCB	535	11.8%	517	11.2%	457	10.6%	8.2%
BMS	3,096	18.9%	4,090	23.2%	6,647	31.3%	(12.4)%	Kyowa Hakko Kirin	530	15.2%	542	15.9%	478	13.6%	5.4%
Boehringer	2,808	13.9%	2,461	11.4%	3,018	15.6%	(3.5)%	Dainippon ³	421	10.9%	250	7.2%	204	5.8%	43.7%
Baxter	2,677	17.5%	2,976	20.7%	2,863	20.6%	(3.3)%	STADA	335	12.5%	268	11.0%	159	7.0%	44.9%
Abbott	2,629	12.0%	1,894	8.8%	1,629	7.6%	27.0%	Lundbeck	285	10.5%	307	11.7%	604	21.2%	(31.4)%
Merck KGaA	2,138	14.5%	1,280	8.6%	1,503	11.0%	19.3%	Forest Labo. ³	112	3.1%	(76)	(2.5)%	1,200	26.4%	(69.4)%
Otsuka ³	1,984	13.7%	1,694	13.9%	1,484	12.9%	15.6%	Ranbaxy ⁵	92	5.1%	300	13.9%	281	15.7%	(42.7)%
Teva	1,649	8.1%	2,205	10.9%	3,109	17.0%	(27.2)%	Hospira	17	0.4%	59	1.4%	57	1.4%	(45.4)%
Takeda ³	1,391	8.2%	649	4.2%	2,646	17.6%	(27.5)%	Valeant	(410)	(7.1)%	80	2.3%	300	12.4%	(73.3)%
J&J ¹								Actavis	(423)	(4.9)%	316	5.3%	523	11.4%	(40.0%)
Gilead	4,524	40.4%	4,010	41.3%	3,790	45.2%	9.3%	Servier	. ,						
Biogen Idec	2,516	36.3%	1,856	33.6%	1,725	34.2%	20.8%	Menarini							
Celgene	1,809	27.9%	1,746	31.7%	1,443	29.8%	12.0%	Purdue Pharma							

Big Pharma companies

Mid Pharma companies

Companies for which overall financial statements are not available

* Restated at constant rates currency using the 2013 Federal Reserve average exchange rates

¹ Excluding the consumer segment -² Excluding crop science and material science segments – ³ Revenues as at 31 March 2014, 31
 ¹ Excluding the consumer segment -² Excluding crop science and material science segments – ³ Revenues as at 31 March 2014, 31
 ¹ March 2013 and 31 March 2012 – ⁴ Revenues as at 30 June 2014, 30 June 2013 and 30 June 2012 – ⁵ Revenues as at 31 March 2014 (pro-rated on a 12 months basis) and as at 31 December 2012 and 31 December 2011 - ⁶ Changes estimated for the period 2011 - 2012

Sources: Annual reports - Smart Pharma Consulting analyses

Performance & Organization of most successful mid pharma companies


23



7. Appendices

The average operating margin is lower and more heterogeneous for Mid Pharma companies compared to Big Pharma companies

Selected high performing mid-pharma companies – Operating income as a % of revenues (2013)




Comparison of the top 50 pharma companies

Sources: Annual reports - Smart Pharma Consulting analyses



7. Appendices: Performance & Organization of most successful pharma companies

GILEAD										
Key Financial Data										
USD million	2013	201	2 2	2011						
Revenues	11,202	9,70	38	3,384						
Net Sales	10,804	9,39	8 8	3,102						
Operating Profit Operating profit margin	4,524 40.4%	4,01 41.39		3,790 45.2%						
R&D expenses % of revenues	2,120 18.9%	1,76 18.19		1,229 14.7%						
Key Products										
	Sales YoY Share of (USD million) % Change revenues									
1. ATRIPLA Antiretroviral agent (V		3,648	2%	33%						
2. TRUVADA Antiretroviral agent (V		3,136	-1%	28%						
3. VIREAD Antiretroviral agent (VIH and Hepatitis B)		959	13%	9%						
4. COMPLERA/EV Antiretroviral agent (V		809	236%	7%						
5. STRIBILD Antiretroviral agent (V	IH)	539	937%	5%						
6. LETAIRIS Antihypertensive agen (pulmonary arterial hy)		520	27%	5%						
7. RANEXA Antianginal agent (che		449	20%	4%						



Pipeline (as of October 2014)									
Number of compounds at each stage	Phase I	Phase II	Phase I	II Filing					
Oncology	1	4	3						
Virology Mostly HBV and HCV	3	6	2	1					
HIV/AIDS		1	1	2					
Cardiovascular	5	1	1						
Respiratory Pulmonary Fibrosis and Respiratory Syncitial Virus		2							



Gilead

 Momelotinib is an investigational JAK inhibitor that has shown promise for the treatment of myelofibrosis, a blood disorder. This molecule was added to Gilead's development pipeline through the acquisition of YM BioSciences

Sources: 2013 Annual report, Smart Pharma Consulting analysis



7. Appendices: Performance & Organization of most successful pharma companies Biogen Idec

bioger	n in		•		Key Se	gments		Strategic Priorities
					Other 7%			 Near-term growth prospects driven by Tecfidera, that is expected to represent the largest contributor to the overall revenue growth in 2014
USD million	2013			2011		013		 Entering into a long-term growth driven by multiple potential new
_						enues 932		product launches
Revenues Net Sales	6,932 6,668			5,049 4,833		million		 Building an innovative pipeline to sustain longer-term value creation
Operating Profit Operating profit margin	2,516 36.3%	1,8	56	1,725 34.2%			_ USA 70%	Deal Strategy
R&D expenses	1,444		35	1,220		1		■ In 2011:
% of revenues	20.8%	24.2	2%	24.2%	Rx branded drugs		96%	- Worldwide collaboration with Portola Pharmaceuticals
ł	Key Pro	ducts			Generics & Biosimilars Vaccines			■ In 2012:
	(Sales USD million)	YoY % Change	Share of revenues	OTC & Consumer Health Medical Devices & Diagnostics			 Joint venture with Samsung, creating Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals
1. AVONEX Immunological agent		3,005	3%	43%	Other (Healthcare) Animal Health			 Acquisition of Stromedix, a privately held company involved in the discovery of antibodies designed to treat fibrosis disorders
(multiple sclerosis) 2. TYSABRI		1,526	34%	22%	Other Segments	4%		- In 2013:
Immunological agent		1,020		2270	Dipolino (as a	5 October 1		 Acquisition of the full ownership of Tysabri from Elan
(multiple sclerosis) 3. RITUXAN/MAB	HERA	1,126	-1%	16%	Pipeline (as o			 Platform agreement with Adimab
Antineoplastic (non-H cancer)	odgkin				Number of compounds at each stage Phase I	Phase II	Phase III Filing	 Research collaboration with Isis: discovery level research, development and commercialization of antisense and other
4. TECFIDERA Psychoanaleptic		876	N/A	13%	Neurology Lupus/Alzheimer/ 3	3	1	therapeutics for the treatment of neurological disorders
(multiple sclerosis)		74	29%	10/	Neuropathic pain Respiratory			 Research and license agreement with Proteostasis
5. FAMPYRA Psychoanaleptic		74	29%	1%	Pulmonary Fibrosis	1		■ In 2014:
(multiple sclerosis) 6. FUMADERM		60	1%	1%	Oncology		3 (MAb)	 Collaboration agreement with Sangamo focused on the development of therapeutics for hemoglobinopathies
Therapy for psoriasis (multiple sclerosis)		50		170	Inflammation Multiple Sclerosis	1	2 (MAb)	Collaboration agreement with Eisai to develop and commercialize Alzheimer's disease treatment

Sources: 2013 Annual report, Smart Pharma Consulting analysis

26



7. Appendices: Performance & Organization of most successful pharma companies Celgene

Cal	cono			8		Key Seg	gments			Strategic Priorities	
						Other 7%				 Delivery of outstanding financial results while investing for future growth 	
Key Financial Data										 Establishment of global commercial operations 	
USD million 2013		2013	2012		2011	Europe 29% USD million Rx branded drugs 98%				R&D productivity (regulatory approvals and successful	
		6,494	•		4,843				commercialization of new products and new product indications; excellence in execution of phase III clinical trials)		
Operating Profit 1,80		6,362 1,809 27.9%	1,746		4,700 1,443 29.8%				 Development of deep, diverse pipeline with differentiated compounds focused on serious unmet needs (hematology, oncology, inflammation & immunology and early discovery) 		
		2,226			1,600				 External partnerships 		
% of revenues 34.3% 31.3% 33.0%					Generics & Biosimilars						
Key Products									Deal Strategy		
			Sales YoY (USD million) % Change		Share of revenues	OTC & Consumer Health Medical Devices & Diagnostics				 Acquisitions are aimed at strengthening research and manufacturing capabilities, as well as enhancing commercialized 	
4 DE			4,280	14%	66%	Other (Healthcare)				products. Recent acquisitions include:	
Imm	nunological agent nunological agent nutiple myeloma)		4,200	14 %	00 %	Animal Health Other Segments	2%			 In 2008, Pharmion for USD 2.9 B (global biopharmaceutical company that acquired, developed and commercialized innova- 	
	2. VIDAZA ¹ Antineoplastic agent		803		-2% 12%	Pipeline (as of October 2014)				 products for the treatment of hematology and oncology patients In 2010, Abraxis for USD 3.2 B (biotechnology company focuse 	
(leukemia and myeloma) 3. ABRAXANE			649	52%	5 10%	Number of compounds at each stage Phase I Phase II Phase III Filing			Filing	 on cancer and other critical illnesses) In 2010, Gloucester for USD 338.2 M plus up to USD 300 M in contingent regulatory milestone payments (company focused of the second second	
Anti	ineoplastic agent east and pancreatic can	ncer)		0270	10,0	Hematology Lymphoma, MDS, AML, CLL ² 6	6	10	1	hematological cancers and other hematological malignancies)	
-	MALYST/IMNO	VID ¹	305	2545%	5%	Oncology Breast, Pancreatic, Gastric		2	1	 In 2012, Avila Therapeutics for USD 352.2 M plus up to USD 55 M in contingent payments (focused on the design and 	
(mu	(multiple myeloma)					Inflammation Arthritis, Dermatitis, 6 Psoriasis, Crohn's disease	5	1	2	development of targeted covalent drugs)Celgene is part of many R&D and commercial agreements and	
Lep	IALOMID prostatic agent		244	-19%	4%	Anemia ³	6			alliances: collaboration arrangements in R&D are deemed important as they can provide the catalysts for future growth	
(mu	ıltiple myeloma)					Cellular Therapies 2 Wound, Crohn's disease			2		

Sources: 2013 Annual report, Smart Pharma Consulting analysis

¹ Orphan drug designation ² MDS: Myelodysplatic Syndromes, AML: Acute Myeloid Leukemia, CLL: Chronic Lymphocytic Leukemia ³The drug in development is sotatercept, a soluble fusion protein, and the first in a novel class of anemia therapies, not an EPO-based product or EPO-mimetic

Performance & Organization of most successful mid pharma companies

January 2015

